实用医学杂志2025，Vol.41Issue(18)：2786-2795,10.DOI:10.3969/j.issn.1006-5725.2025.18.002
基于类器官构建泛TKI提高ET+CDK4/6抑制剂治疗HR+/HER2-low乳腺癌疗效的筛选工具
Development of an organoid-based pan-TKI precision screening platform to enhance therapeutic efficacy of ET+CDK4/6 inhibitors in HR+/HER2-low breast cancer
摘要
Abstract
Objective To investigate the underlying mechanisms contributing to the limited therapeutic efficacy of endocrine therapy combined with CDK4/6 inhibitors in HR+/HER2-low breast cancer,and to develop a breast cancer organoid model as a tool for the precise identification of HR+/HER2-low patients who are responsive to pan-TKI treatment.Methods Transcriptomics was employed to identify differentially expressed genes in HR+/HER2-0 and HR+/HER2-low breast cancer samples and to perform functional enrichment analysis.Tumor organoid models were established using breast cancer tissues obtained from clinical sources,and the differential sensitivity of these samples to therapeutic agents was assessed using Calcein-AM/PI cell viability staining and EdU-based cell proliferation assays.Results The results of transcriptomic enrichment analysis indicated that EGFR was signifi-cantly activated in HR+/HER2-low breast cancer and exhibited characteristics of resistance to TKIs.Breast cancer organoids were successfully established.Drug sensitivity testing revealed that the therapeutic efficacy of ET combined with CDK4/6 inhibitors was suboptimal in certain cases of HR+/HER2-low breast cancer,while the addition of TKIs effectively restored sensitivity to the ET+CDK4/6 inhibitor regimen(P<0.05).Conclusions TKI can restore the reduced sensitivity of HR+/HER2-low breast cancer to endocrine therapy combined with CDK4/6 inhibitors.Breast cancer organoids hold promise as screening tools for assessing drug sensitivity in clinical settings for patients with HR+/HER2-low breast cancer.关键词
乳腺癌/HR+/HER2-low/ET+CDK4/6抑制剂/类器官/酪氨酸激酶抑制剂Key words
breast cancer/HR+/HER2-low/ET+CDK4/6 inhibitor/organoid/tyrosine kinase in-hibitor分类
医药卫生引用本文复制引用
吴迎朝,陈柳汕,梁裕琪,陈洁婷,黄俊峰,左谦,陈前军..基于类器官构建泛TKI提高ET+CDK4/6抑制剂治疗HR+/HER2-low乳腺癌疗效的筛选工具[J].实用医学杂志,2025,41(18):2786-2795,10.基金项目
国家自然科学基金项目(编号:82474504) （编号:82474504）
中医药广东省实验室(横琴实验室)科技研发培植项目(编号:HQL2024PZ023) （横琴实验室）
中国初级卫生保健基金会项目(编号:KYJJ20240509) （编号:KYJJ20240509）
广州市科技计划项目(编号:2024A03J0850,SL2024A04J3296) （编号:2024A03J0850,SL2024A04J3296）
广州中医药大学与中山市中医院高水平医院共建项目学科建设专项(编号:GZYZS2024XKG05) （编号:GZYZS2024XKG05）
北京迈迪科公益基金会科研基金(编号:MDK学研字2023-1007) （编号:MDK学研字2023-1007）
北京科创医学发展基金会(编号:KC2021-ZZ-0010-9,KC2023-JX-0082-12) （编号:KC2021-ZZ-0010-9,KC2023-JX-0082-12）
